These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 9392308

  • 1. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 2. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 4. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus infections in children after transplantation of the small intestine.
    Finn L, Reyes J, Bueno J, Yunis E.
    Am J Surg Pathol; 1998 Mar 15; 22(3):299-309. PubMed ID: 9500771
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.
    Pediatr Transplant; 1999 Feb 15; 3(1):22-6. PubMed ID: 10359027
    [Abstract] [Full Text] [Related]

  • 7. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 9. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb 15; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 10. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS, Ho MC, Hu RH, Wu JF, Chen HL, Ni YH, Hsu HY, Jeng YM, Chang MH.
    J Formos Med Assoc; 2019 Sep 15; 118(9):1362-1368. PubMed ID: 30612881
    [Abstract] [Full Text] [Related]

  • 11. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
    Cao S, Cox K, Esquivel CO, Berquist W, Concepcion W, Ojogho O, Monge H, Krams S, Martinez O, So S.
    Transplantation; 1998 Oct 15; 66(7):851-6. PubMed ID: 9798693
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center.
    Dogan B, Sema YA, Bora K, Veysel U, Benan D, Ezgi KT, Gozde AK, Demir D, Ozsan N, Hekimgil M, Zumrut SB, Miray K, Funda C, Sema A.
    J Med Virol; 2024 Jun 15; 96(6):e29767. PubMed ID: 38932460
    [Abstract] [Full Text] [Related]

  • 13. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 15; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 14. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul 15; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 15. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Cacciarelli TV, Reyes J, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Green M.
    Pediatr Transplant; 2001 Oct 15; 5(5):359-64. PubMed ID: 11560756
    [Abstract] [Full Text] [Related]

  • 16. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM.
    Transplantation; 2002 May 27; 73(10):1603-10. PubMed ID: 12042647
    [Abstract] [Full Text] [Related]

  • 17. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
    Fukushima D, Sato K, Kawagishi N, Ohuchi N, Satomi S.
    Transplantation; 2015 Jan 15; 99(1):114-9. PubMed ID: 24846306
    [Abstract] [Full Text] [Related]

  • 19. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 20. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.